Search results
21 mar 2023 · Overview of manufacturing of allogenic ‘off‐the‐shelf’ Epstein–Barr virus (EBV)‐specific T‐cell therapy for the treatment of multiple sclerosis (MS) patients. Peripheral blood mononuclear cells from healthy EBV seropositive individuals are stimulated with a recombinant replication‐deficient adenovirus encoding EBV antigens.
- Epstein-Barr virus-specific T cell therapy for progressive multiple ...
EBV-infected autoreactive B cells might accumulate in the...
- Epstein-Barr virus-specific T cell therapy for progressive multiple ...
11 lis 2018 · An open-label phase I trial was designed to treat 5 patients with secondary progressive MS and 5 patients with primary progressive MS with 4 escalating doses of in vitro–expanded autologous EBV-specific T cells targeting EBV nuclear antigen 1, latent membrane protein 1 (LMP1), and LMP2A.
The confirmation of a link between EBV and MS, however, now offers the opportunity to develop novel targeted treatments, from antivirals to cell-based therapies.
15 lis 2018 · EBV-infected autoreactive B cells might accumulate in the CNS because of defective cytotoxic CD8+ T cell immunity. We sought to determine the feasibility and safety of treating progressive MS patients with autologous EBV-specific T cell therapy.
11 mar 2022 · Targets of EBV-directed therapy include (1) vaccination to prevent development of MS, (2) anti-viral therapy to eliminate latent EBV infection, (3) B cell therapy to modulate EBV pathogenic B cells, and (4) T cell therapy to modulate EBV pathogenic T cell responses.
15 lis 2018 · Methods: An open-label phase I trial was designed to treat 5 patients with secondary progressive MS and 5 patients with primary progressive MS with 4 escalating doses of in vitro-expanded...
7 lut 2023 · Understanding whether disease-modifying therapies interfere with EBV infection or the anti-EBV immune response could help verify whether EBV is needed after disease onset and, hence, could advance therapeutics, even in the absence of specific anti-EBV treatments.
